ScholarIQanswers from OpenAlex
Istanbul University-Cerrahpaşa
InstitutionResearch output, impact & collaborations
Istanbul University-Cerrahpaşa is a institution indexed in ScholarIQ from OpenAlex.
What is known about Istanbul University-Cerrahpaşa?
ScholarIQrecord summary
Istanbul University-Cerrahpaşa is a research organisation in Istanbul, TR. OpenAlex records 27,995 works and 719,594 citations for it. 8,484 researchers list it as their most recent affiliation.
How many works does Istanbul University-Cerrahpaşa have?
ScholarIQindexed works
Istanbul University-Cerrahpaşa has 27,995 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Istanbul University-Cerrahpaşa have?
ScholarIQcitation count
Istanbul University-Cerrahpaşa has 719,594 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Istanbul University-Cerrahpaşa?
ScholarIQresearcher count
Istanbul University-Cerrahpaşa has 8,484 researchers in the ScholarIQ index.
What is the average h-index at Istanbul University-Cerrahpaşa?
ScholarIQavg h-index
Istanbul University-Cerrahpaşa has an average h-index of 36 in OpenAlex.
What is the ROR of Istanbul University-Cerrahpaşa?
ScholarIQror
The ROR for Istanbul University-Cerrahpaşa is on the source record.
What is the OpenAlex record for Istanbul University-Cerrahpaşa?
ScholarIQopenalex
The OpenAlex for Istanbul University-Cerrahpaşa is on the source record.
Who are the most-cited researchers behind Istanbul University-Cerrahpaşa?
ScholarIQtop researchers by citations
What are the most-cited papers on Istanbul University-Cerrahpaşa?
ScholarIQmost cited works
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocák, Gwénaëlle Gravis, I. Bodrogi, Mary J. MacKenzie, Liji Shen, Martin Roessner, Sunil Gupta, Oliver Sartor
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N.
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel
How much of the research on Istanbul University-Cerrahpaşa is open access?
ScholarIQopen access share
92%OPEN ACCESS